Compare W W Grainger Inc (GWW) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Merck & Co., Inc. — how do they compare? W W Grainger Inc trades at $1,289.35 (market cap $59.76B), while Merck & Co., Inc. trades at $146.29 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 5.9× W W Grainger Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold W W Grainger Inc for 25 Days and Merck & Co., Inc. for 98 Days on average.
| GWW | MRK | |
|---|---|---|
Market Cap | $59.76B | $351.28B |
Volume | 186,697 | 7,969,665 |
Sector | Industrials | Health |
52-Week High | $1.40K | $156.43 |
52-Week Low | $918.18 | $82.49 |
Typical Hold Time | 25 Days | 98 Days |
Enterprise Value | $61.96B | $398.04B |
Dividend Yield | 0.79% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GWW trades at $1,289.79, up 2.08% today, with a bearish technical signal but strong fundamentals including a 47.92% ROE and recent earnings beats. The company reported Q2 2026 EPS of $12.01, beating expectations, and maintains a net income margin of 9.92%. Recent developments include the acquisition of technology assets from Adroit Worldwide Media for $210 million and the opening of a new distribution center in Oregon, supporting growth initiatives.
The outlook is mixed: analyst consensus is a hold with a $1,310 price target, but strong profitability and strategic acquisitions offer upside. Risks include high valuation multiples like a P/E of 32.34 and competitive pressures in industrial distribution. Cash flow trends improved in 2026, with net cash flow near breakeven, reducing liquidity concerns.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
